Turnover
≈ €320,000 estimated
The micro format states no turnover.
VAXXCellence
Lifetime
1 annual account with figurespeak €126,766 (2025)
€126,766
peak €88,139 (2025)
€88,139
peak €103,139 (2025)
€103,139
€44,992
Board1 name since 2024
1 directorvan der MOST Robbert Gerrit
Documentsfilings and deeds
03-07-202628 days before the deadline
2025micro format
Registered office moved from Overijse to Antwerp 17-10First year with figures
Key points
from the 2025 annual accountsStarting capital
€15,000 100 shares
Checked score
93
Excellent
Financially stronger than 76% of micro companies in research and development (NACE 72)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 932 companies (NACE 72, micro).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
07-2025: 0.7%
08-2025: 0.7%● unchanged vs 07-2025
09-2025: 0.7%● unchanged vs 08-2025
10-2025: 0.7%● unchanged vs 09-2025
11-2025: 1.3%▲ +0.6 percentage points vs 10-2025
12-2025: 1.4%▲ +0.1 percentage points vs 11-2025
01-2026: 1.4%● unchanged vs 12-2025
02-2026: 1.5%▲ +0.1 percentage points vs 01-2026
03-2026: 1.5%● unchanged vs 02-2026
04-2026: 1.5%● unchanged vs 03-2026
05-2026: 1.6%▲ +0.1 percentage points vs 04-2026
06-2026: 1.6%● unchanged vs 05-2026highest value
07-2026: 1.6%● unchanged vs 06-2026highest value
08-2026: 0.2%▼ -1.4 percentage points vs 07-2026lowest value
09-2026: 0.2%● unchanged vs 08-2026lowest value
10-2026: 0.2%● unchanged vs 09-2026lowest value
11-2026: 0.2%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
raises risk
1 change of registered office in 24 months
lowers risk
Liquidity: current ratio 2.82, cash €68,211
Sector: Scientific research and development (NACE 72)
Equity €103,139 (69.6% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 61% of them on solvency, 76% on liquidity and 90% on profitability.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 39,278 companies had the same profile as VAXXCellence has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of VAXXCellence itself is lower: 0.2% within 12 months. It rests on far more data about VAXXCellence than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for VAXXCellence. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €9,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity is ample, with a current ratio of 2.82, above the usual 1.5. Short-term debt is 29.9% and cash 46% of total assets. 30.4% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
28 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
Recent changes
Registered office moved from Overijse to Antwerp
New registered office: Tabaksvest 87 Bus 4593, 2000 Antwerpen · Previous registered office: Warandelaan 7, 3090 Overijse · Board meeting of 19-08-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1010780382
First establishment
Warandelaan 7, Overijse
Incorporation
Founding capital of €15,000, 100 shares · Founder: van der MOST Robbert Gerrit · Appointment: van der MOST Robbert Gerrit (director) · published on 28-06-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VAXXCellence Antwerp | €148,132 | €126,766 | 69.6% | - |
| Vandierendonck Bieke Bruges | €119,598 | €105,360 | 46.3% | - |
| JLE-O Berchem-Sainte-Agathe | €210,497 | €200,459 | 72.1% | - |
| GMK Consulting Grimbergen | €225,649 | €169,196 | 86.1% | - |
| BOTTOMLEY CONSULTING GROUP Overijse | €231,718 | €112,867 | 74.8% | - |
| Metheion Technology & Engineering Consulting Leuven | €100,275 | €80,942 | 67.4% | - |
| Mulltron Antwerp | €80,357 | €80,299 | 84.5% | - |
These companies have the same main activity as VAXXCellence: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €80,400 and €232,000, founded between 2023 and 2025.
Official details
Source: KBO- Status
- Active since 26-06-2024Normal situation
- Registered office
- 202 active companies are registered at this address72 started in the 12 months before. Source: KBO register, as of 9 November 2026.
- Activity
- Other research and development on natural sciencesNACE 72109and 2 others
- Establishment unit
- 2.361.599.7113090 Overijse, since 01-07-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 14-04-2025
Annual accounts 2025
- €148,132
- Filing
- Filed on 03-07-2026, 28 days before the end of the filing period
Insights on VAXXCellence
VAXXCellence has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €103,139 and a net result of €88,139.
Its solvency ranks better than 59% of 619 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about VAXXCellence
- What is the company number of VAXXCellence?
- The company number of VAXXCellence is 1010.780.382. The VAT number is the same number with BE in front: BE 1010.780.382.
- Where is VAXXCellence based?
- The registered office is at Tabakvest 87, 2000 Antwerp.Company details
- What does VAXXCellence do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of VAXXCellence?
- VAXXCellence is a private limited company (BV).
- When was VAXXCellence founded?
- VAXXCellence was founded on 26-06-2024.
- Is VAXXCellence still active?
- Yes, VAXXCellence is an active enterprise in the KBO register.
- What is the turnover of VAXXCellence?
- The turnover in financial year 2025 is ≈ €320,000. This figure is estimated from the gross margin of €126,766 and 2,205 comparable companies of the same size. It probably lies between €210,000 and €490,000. It is a rough estimate.Financials
- Is VAXXCellence profitable?
- In financial year 2025, VAXXCellence made a profit of €88,139.
- Where can I find the annual accounts of VAXXCellence?
- VAXXCellence filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark Estimate what this company is worth.Value indication
See how customers, suppliers and banks see your own company and what to improve first.